TCM
ELVN icon

TCG Crossover Management’s Enliven Therapeutics ELVN Stock Holding History

TCG Crossover Management’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-498,000
Closed -$9.99M – 44
2025
Q2 		$9.99M Buy
+498,000
New +$9.43M 1.14% 26

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

TCG Crossover Management's ELVN Position: Q3 2025 in Review

TCG Crossover Management sold out of Enliven Therapeutics (ELVN) in Q3 2025, closing a stake of 498,000 shares — an estimated $9.99M sold.

TCG Crossover Management first reported a position in ELVN in Q2 2025 and held it in 1 quarter. The position peaked at $9.99M in Q2 2025. 134 funds tracked by Wall St. Rank hold ELVN as of Q3 2025.

  • TCG Crossover Management reported no remaining Enliven Therapeutics position as of Q3 2025 after selling out during the quarter.
  • TCG Crossover Management sold 498,000 Enliven Therapeutics shares in Q3 2025, an estimated $9.99M.
  • TCG Crossover Management first reported a position in Enliven Therapeutics in Q2 2025 and held it in 1 quarter.
  • TCG Crossover Management's Enliven Therapeutics position peaked at $9.99M in Q2 2025.
  • 134 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q3 2025.

Based on TCG Crossover Management's 13F filing for Q3 2025, filed 17 Nov 2025.